# AlpalifeBio

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/alpalifebio

- Industry: Healthcare
- Headquarters: Shenzhen, China
- Website: www.ktsm-life.com
- Total disclosed funding: $9.8M
- Latest round: Series A (Sep 9, 2025)
- Investors on record: 4

## About

Founded in 2016 and based in Shenzhen, China, AlpalifeBio focuses on developing and providing nanobody technologies. In September 2025, AlpalifeBio raised CNY 70 million in Series A+ funding from new investors Jolmo Capital, Livzon Pharmaceutical Group Inc., Galaxy Capital and Nanling Fund. AlpalifeBio specializes in the development and provision of nanobody technologies, focusing specifically on discovering and producing nanobodies that target G protein-coupled receptors (GPCRs). The company offers a variety of research products, including tagged nanobody beads, recombinant nanobodies, and protein purification materials, essential for various biomedical research applications. Utilizing advanced protein expression systems such as insect, mammalian, yeast, and E. coli cells, AlpalifeBio generates high-quality proteins for pharmaceutical development, serving a global clientele that includes academic institutions, pharmaceutical companies, and biotechnology firms.
The company generates revenue mainly through the sale of its proprietary nanobody products and Contract Research Organization (CRO) services. The company operates a B2B model, engaging clients in purchasing agreements for research reagents and services, including multi-year contracts for ongoing research support related to nanobody-based therapies. Revenue is further enhanced through strategic partnerships and collaborations with other firms.

## Funding rounds

- Series A, Sep 9, 2025, $9.8M — Jolmo Capital, Galaxy Capital, Nanling Fund, Livzon Pharmaceutical Group Inc.

## Investors

- Jolmo Capital (https://capitalatlas.ai/funds/jolmo-capital) — Series A
- Galaxy Capital (https://capitalatlas.ai/funds/galaxy-capital) — Series A
- Nanling Fund — Series A
- Livzon Pharmaceutical Group Inc. — Series A